Combining Molecularly Targeted Agents: Is More Always Better?
MetadataShow full item record
The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials. <i>Clin Cancer Res; 23(5); 1123-5. ©2016 AACR</i><i>See related article by Calvo et al., p. 1177</i>.
Version of record
Antineoplastic Combined Chemotherapy Protocols
Molecular Targeted Therapy
Medicine Drug Development Unit (de Bono)
Gastrointestinal Cancer Biology and Genomics
License start date
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, 23 (5), pp. 1123 - 1125